BRCA2 and neoplasm: In this report, tumor growth and survival time were observed and compared in mice with Pdx1-Cre, LSL-K-rasG12D and a germline heterozygosity for Brca2 Tr/Δ11 background, and Pdx1-Cre, LSL-K-rasG12D mutant mice, and they found that the median survival for Pdx1-Cre, LSL-K-rasG12D, Brca2 Tr/Δ11 mice is significantly shorter by approximately 5 months.